Lack of Influence of Non-Overlapping Mutations in IBRAF/I, INRAS/I, or INF1/I on 12-Month Best Objective Response and Long-Term Survival after Checkpoint Inhibitor-Based Treatment for Metastatic Melanoma

Most melanoma patients have non-overlapping "driver" mutations in either BRAF, NRAS, or NF1 genes based on Next-Gen sequencing. Other overlapping genetic changes, termed "passenger mutations" may also be identified. The impact of these mutations on cancer immunotherapy outcome is...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cancers 2023-07, Vol.15 (13)
Hauptverfasser:	Panning, Alyssa, Samlowski, Wolfram, Allred, Gabriel
Format:	Artikel
Sprache:	eng
Schlagworte:	Analysis Antimitotic agents Antineoplastic agents Cancer Care and treatment Development and progression Drug therapy Genetic aspects Immunotherapy Metastasis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!